Clinical trials: Antiphospholipid Syndrome (APS)
Recurrent Pregnancy Losses, Positive Anti Phospholipid Syndrome
Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome
Preconceptional use of low molecular weight heparin (enoxaparin) and aspirin in patient with recurrent miscarriages with positive anti phospholipid antibodies increase the implantation rate and the duration of pregnancy with low…
- Trial name
- NCT01661439
- Testing
- low molecular weight heparin (enoxeparine)
- Where
- Egypt
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Woman's Health University Hospital, Egypt
Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can…
- Trial name
- PROMISSE (NCT00198068)
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Antiphospholipid Syndrome (APS)
Effect of Belimumab on Antibody Titers in Primary APS Patients
The purpose of this study is to evaluate the regulatory effect of Belimumab on the antiphospholipid antibody (aPL) as well as to observe related past and new clinical events in primary antiphospholipid syndrome patients.
- Trial name
- NCT06747312
- Testing
- Belimumab+SOC, SOC
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Antiphospholipid Syndrome (APS)
Pilot Study of Gut Commensals in Antiphospholipid Syndrome
The purpose of this study is to explore if certain commensals within the gut microbiota (the collection of all microbes that live inside the gut) correlate with autoantibodies in the autoimmune clotting disorder called…
- Trial name
- NCT01787305
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Yale University
Antiphospholipid Syndrome (APS)
Effect of Telitacicept on Antibody Titers in Primary APS Patients
The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles.
- Trial name
- NCT06315530
- Testing
- Telitacicept+SOC, SOC
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital